Postdoctoral Fellow Alberta Diabetes Institute, University of Alberta, Canada
Disclosure(s):
Alice Carr, PhD: No financial relationships to disclose
With the recent approval of the first disease-modifying drug for type 1 diabetes (T1D), Teplizumab, this session will explore the potential of expanding Continuous Glucose Monitoring (CGM) beyond its FDA-approved use in managing clinical T1D, to early-stage disease. We’ll highlight CGM’s key advantages over current clinical trial endpoints - minimal invasiveness, remote monitoring, and low cost - and discuss the advancements needed to position CGM as a reliable screening, staging, and surveillance tool to address the unmet need in early-stage T1D clinical trials.
